Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Hematol
Päätekijät: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean‐Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Shen, Juan, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2020
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317815/
https://ncbi.nlm.nih.gov/pubmed/32129512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25777
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia